Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 56

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Seasonal allergy

Not yet recruiting

Dose-finding study of sublingual immunotherapy with phleum pratense extract (vs sodium chloride) in patients with grass pollen allergic rhinitis

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Phleum Pratense
  • Sponsor:Asac Pharmaceutical Inmunology S.A.

Giant cell arteritis+1

Not yet recruiting

Diagnostic Accuracy of 68Ga‑FAPI‑46 PET/CT in Patients with Suspected Giant Cell Arteritis and Polymyalgia Rheumatica

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Universitair Medisch Centrum Groningen

Type 1 diabetes mellitus

Not yet recruiting

Study of the efficacy and safety of ladarixin and rabbit anti-human thymocyte immunoglobulin in adolescents and adults with new-onset type 1 diabetes

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Ladarixin
  • Sponsor:Ospedale San Raffaele S.r.l.

Graft versus host disease

Not yet recruiting

Study of Mesenchymal Stromal Cells expressing CXCR4 and IL-10 for patients with acute Graft Versus Host Disease who do not respond to steroids or ruxolitinib

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:ALLOGENEIC ADIPOCYTE-DERIVED MESENCHYMAL STROMAL CELLS TRANSDUCED WITH A LENTIVIRAL PROVIRUS VECTOR CONTAINING THE HUMAN CXCR4 AND IL-10 GENES
  • Sponsor:Fundacion Instituto De Investigacion Sanitaria De Navarra

Colitis ulcerative

Not yet recruiting

A study comparing vedolizumab, filgotinib, ustekinumab, and infliximab to maintain remission in patients with ulcerative colitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Filgotinib
  • Sponsor:University Hospital Of Clermont-Ferrand

Axial spondyloarthritis

Not yet recruiting

A study comparing bimekizumab and adalimumab for treating chest pain in patients with active axial spondyloarthritis who do not respond well to non-steroidal anti-inflammatory drugs.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Adalimumab
  • Sponsor:Centre Hospitalier Universitaire Rouen

Vitiligo

Not yet recruiting

A study to evaluate the effectiveness of oxygen and narrow-band UVB phototherapy for treating patients with diffuse vitiligo

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen
  • Sponsor:Centre Hospitalier Universitaire De Nice

Colitis ulcerative

Not yet recruiting

Study on the use of oral vancomycin for children with ulcerative colitis

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Vancomycin Hydrochloride
  • Sponsor:Pirkanmaan hyvinvointialue

Rheumatoid arthritis

Not yet recruiting

A study to compare two different dosing methods of tocilizumab in patients with rheumatoid arthritis who have low disease activity or are in clinical remission

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Centre Hospitalier Universitaire De Nice

Polymyalgia rheumatica

Not yet recruiting

A study to evaluate the safety and effectiveness of resomelagon in patients with polymyalgia rheumatica who are in remission using glucocorticoids

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Resomelagon
  • Sponsor:Synact Pharma ApS

Axial spondyloarthritis+1

Not yet recruiting

Study to evaluate the effect of upadacitinib on the frequency of eye inflammation in patients with axial spondyloarthritis.

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:Care Arthritis Ltd.

Type 1 diabetes mellitus+1

Not yet recruiting

Study of anakinra and a drug combination to prevent blood clots in patients receiving a pancreatic transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.